News Novartis takes aim at Shire and Allergan with dry-eye drug Swiss company takes option on Lubris' ECF843.
News Shire launches potential blockbuster dry eye drug in US Xiidra could be ophthalmology blockbuster.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
